Andexanet alfa: trials just leave us with more questions
Andexanet Alfa in Acute Intracranial Hemorrhage in Patients Receiving an Oral Factor Xa Inhibitor (ANNEXA-I), the first ever randomized controlled trial of a reversal agent for direct oral anticoagulants, was published in 2024. The trial, which randomized patients with intracranial hemorrhage to and...
Saved in:
Main Author: | Richard J. Buka |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2025-01-01
|
Series: | Research and Practice in Thrombosis and Haemostasis |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2475037924003236 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Effect of antithrombotic therapies on small bowel bleeding: an European multicenter retrospective study
by: Lucia Scaramella, et al.
Published: (2025-01-01) -
A new score for predicting intracranial hemorrhage in patients using anticoagulant drugs
by: Fuxin Ma, et al.
Published: (2025-01-01) -
Severe Airway Obstruction due to Massive Retropharyngeal Hematoma in a Warfarin-Taking Patient with a Normal International Normalized Ratio
by: Hyun Young Cho, et al.
Published: (2021-03-01) -
Management of Ruptured Intracranial Aneurysm with Deep Vein Thrombosis
by: Sneha Pandit, et al.
Published: (2024-09-01) -
Liver function after transplantation in the assessment of the coagulation system and the concept of antithrombotic therapy
by: Marceli Lukaszewski, et al.
Published: (2020-03-01)